Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025Turkish Journal of Clinics and LaboratoryOpen Access

Bladder-sparing trimodal therapy in elderly patients with muscle-invasive bladder cancer: a real-world single-center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

VAVolkan AslanHAHüseyin AtacanAUAybala Nur Ucgul

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals improved survival in elderly muscle-invasive bladder cancer patients receiving trimodal therapy, suggesting important prognostic indicators.

Key Points

  • Overall survival estimates showed a median of 22 months for elderly patients with muscle-invasive bladder cancer receiving trimodal therapy.
  • Patients treated with platinum-based chemotherapy had improved overall survival (HR: 0.041; p = 0.015), indicating potential benefits of this approach.
  • Multivariable analysis identified higher platelet-to-lymphocyte ratio and advanced nodal stage as negative predictors of overall survival.
  • The findings support considering bladder-sparing trimodal therapy as a viable treatment for selected elderly patients with early-stage muscle-invasive bladder cancer.

Cite This Study

Aslan et al. (2025) studied this question.

synapsesocial.com/papers/68dd91d5fe798ba2fc498feehttps://doi.org/10.18663/tjcl.1738115
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Management of bladder cancer recurrence following the trimodality therapy2025
  2. 2Prognostic Significance of Pre-Treatment Serum Markers in Muscle-Invasive Bladder Cancer Under Tri-Modality Therapy2025
  3. 3Validation of neutrophil-to-lymphocyte ratio for prognosis and treatment selection in muscle-invasive bladder cancer: A single-institutional longitudinal study2025
  4. 4Prognostic value of combined tumor regression grade and TNM stage in muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy2025
  5. 5Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01)2025